Multiple Sclerosis
Conditions
Keywords
Relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS), Multiple Sclerosis Functional Composite (MSFC), Expanded Disability Status Scale (EDSS)
Brief summary
This observational study is being conducted to evaluate the usefulness of the MSFC and its relationship with EDSS scores in subjects with MS in Argentina.
Detailed description
This observational, open-label study is being conducted to correlate change in EDSS score with the change in MSFC scores at the end of a 2-year follow-up period for subjects with MS in Argentina. Measurement of disability is an indispensable parameter in assessing the efficacy of experimental therapeutic agents in MS as well as in trying to determine possible individual evolution of the disease. Clinical scales are being used as primary or secondary outcome measures for recording disease progression in clinical trials. Kurtzke's EDSS is still used as a gold standard for measuring impairment and disability in MS. The MSFC is an examination-based quantitative scoring of neurological impairment. This study aims to establish a correlation between the usefulness of both scales. OBJECTIVES Primary Objective: * To evaluate the change in MSFC score with change in EDSS scores at end of 2 year follow-up period for subjects with MS in Argentina Secondary Objectives: * To evaluate the cross-sectional correlations in MSFC score at baseline and at 24 months with EDSS score at baseline and at 24 months * To describe the MSFC score for MS phenotype in this population * To evaluate the predictive validity of MSFC score of a subsequent EDSS change in a subgroup of MS patients in Argentina
Interventions
None listed
Sponsors
Merck KGaA, Darmstadt, Germany
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Subjects with definite diagnosis of MS, according to McDonald's criteria * All clinical types: relapsing-remitting MS (RRMS), primary progressive MS (PPMS) and secondary progressive MS (SPMS). Stable disease course without any relapse for at least the previous 3 months * Subjects treated or not with disease modifying drugs * Ages between 18 and 65 years and is capable of understanding and complying with protocol requirements * Subject has a stable residence with no planned move during the entire investigation period
Exclusion criteria
* Life expectancy less than 5 years at admission * Diagnosis of clinically isolated syndrome (CIS) * Other clinical conditions that mimic MS * Psychiatric diseases * Alcohol or drug abuse * Pregnancy * The subject is unwilling or unable to comply with the protocol or scheduled appointments * Subject is unable to understand the language in which the approved informed consent is written * The subject is a study site employee, or an immediate family member (i.e., spouse, parent, child, sibling) of a study site employee, involved in conduct of this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| - Evaluation of correlations between changes over time | Baseline and two years | \- Evaluation of correlations between changes over time for MSFC composite score and arm, leg and cognitive MSFC scores versus EDSS score changes over the same periods |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate the predictive validity of MSFC score of a subsequent EDSS change in a subgroup of MS patients | Baseline, 1 year, 2 years |
Countries
Argentina
Outcome results
None listed